New Clinical Use for Gocovri

New Clinical Use for Gocovri
Adamas announced that the Food and Drug Administration (FDA) approved Gocovri for a second indication – as an add-on treatment to carbidopa/levodopa in Parkinson’s disease (PD) patients who are experiencing OFF episodes. Previously, Gocovri was only approved for treatment of Levodopa-induced dyskinesias. You can learn more about managing dyskinesias and OFF episodes in this webinar. This additional indication acknowledges that ... read more
Source: American Parkinson Disease AssociationPublished on 2021-05-03By Phil Franchina